Shares of Vaccibody (VACC: NO) shot up 46% to 54.00 Norwegian kroner yesterday as the Oslo-based clinical-stage biotech announced an exclusive worldwide license and collaboration agreement with Genentech, a subsidiary of Swiss pharma giant Roche (ROG: SIX), for the development and commercialization of DNA-based individualized neoantigen vaccines for the treatment of cancers.
Vaccibody will conduct development through the end of Phase Ib and Genentech will be responsible for development and commercialization thereafter. The transaction will combine Genentech’s global cancer immunotherapy research, development and commercial leadership with Vaccibody’s targeted DNA-based vaccine platform to realize a potential new treatment paradigm of individualized cancer vaccines.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze